These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 26451524

  • 1. Predicting allopurinol response in patients with gout.
    Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK.
    Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
    [Abstract] [Full Text] [Related]

  • 2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 3. Individualising the dose of allopurinol in patients with gout.
    Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO.
    Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
    [Abstract] [Full Text] [Related]

  • 4. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L, Gow P, Sharples K, Raill B.
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [Abstract] [Full Text] [Related]

  • 5. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
    Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Merriman TR, Wright DFB, Drake J, Dalbeth N.
    Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP, Gilliland WR.
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [Abstract] [Full Text] [Related]

  • 8. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT.
    Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
    Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, Wright DF, Dalbeth N.
    Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
    [Abstract] [Full Text] [Related]

  • 11. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
    Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH.
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
    [Abstract] [Full Text] [Related]

  • 12. The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools).
    Wright DFB, Hishe HZ, Stocker SL, Dalbeth N, Horne A, Drake J, Haslett J, Phipps-Green AJ, Merriman TR, Stamp LK.
    Br J Clin Pharmacol; 2024 May; 90(5):1268-1279. PubMed ID: 38359899
    [Abstract] [Full Text] [Related]

  • 13. Allopurinol: insights from studies of dose-response relationships.
    Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG.
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
    [Abstract] [Full Text] [Related]

  • 14. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR.
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [Abstract] [Full Text] [Related]

  • 15. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
    Wright DF, Doogue MP, Barclay ML, Chapman PT, Cross NB, Irvine JH, Stamp LK.
    Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M.
    J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study).
    Stamp L, Te Karu L, Reid S, Wright DFB, Frampton C, Tuitaupe VS, Dalbeth N.
    BMJ Open; 2024 Aug 03; 14(8):e084665. PubMed ID: 39097306
    [Abstract] [Full Text] [Related]

  • 19. The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout.
    Wilson LC, Ward J, Wright DFB, Green SC, Stocker SL, Putt TL, Schollum JBW, Walker RJ.
    Nephrology (Carlton); 2024 Aug 03; 29(8):547-550. PubMed ID: 38626950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.